CN101534648B - 使用mntf肽及其类似物治疗神经紊乱的方法 - Google Patents

使用mntf肽及其类似物治疗神经紊乱的方法 Download PDF

Info

Publication number
CN101534648B
CN101534648B CN2007800419244A CN200780041924A CN101534648B CN 101534648 B CN101534648 B CN 101534648B CN 2007800419244 A CN2007800419244 A CN 2007800419244A CN 200780041924 A CN200780041924 A CN 200780041924A CN 101534648 B CN101534648 B CN 101534648B
Authority
CN
China
Prior art keywords
mntf
peptide
mice
animals
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007800419244A
Other languages
English (en)
Chinese (zh)
Other versions
CN101534648A (zh
Inventor
P-Y·D·寇
M·S·金迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genervon Biopharmaceuticals LLC
Original Assignee
Genervon Biopharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genervon Biopharmaceuticals LLC filed Critical Genervon Biopharmaceuticals LLC
Publication of CN101534648A publication Critical patent/CN101534648A/zh
Application granted granted Critical
Publication of CN101534648B publication Critical patent/CN101534648B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN2007800419244A 2006-11-10 2007-11-13 使用mntf肽及其类似物治疗神经紊乱的方法 Expired - Fee Related CN101534648B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85802206P 2006-11-10 2006-11-10
US60/858,022 2006-11-10
PCT/US2007/023951 WO2008057609A2 (en) 2006-11-10 2007-11-13 Methods of treating neuronal disorders using mntf peptides and analogs thereof

Publications (2)

Publication Number Publication Date
CN101534648A CN101534648A (zh) 2009-09-16
CN101534648B true CN101534648B (zh) 2013-12-11

Family

ID=39365151

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800419244A Expired - Fee Related CN101534648B (zh) 2006-11-10 2007-11-13 使用mntf肽及其类似物治疗神经紊乱的方法

Country Status (9)

Country Link
US (1) US8673852B2 (enExample)
EP (1) EP2086331B1 (enExample)
JP (1) JP5336384B2 (enExample)
CN (1) CN101534648B (enExample)
AU (1) AU2007317730B2 (enExample)
CA (1) CA2669658C (enExample)
DK (1) DK2086331T3 (enExample)
ES (1) ES2407454T3 (enExample)
WO (1) WO2008057609A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101951942B (zh) * 2008-02-21 2014-09-03 健能万生物制药公司 Mntf肽组合物及使用方法
MY189079A (en) * 2009-12-11 2022-01-25 Univ Case Western Reserve Insulin analogues with chlorinated amino acids
GB201015569D0 (en) * 2010-09-16 2010-10-27 Medical Res Council Blood assay for prions
WO2016210123A1 (en) 2015-06-26 2016-12-29 Genervon Biopharmaceuticals, LLC Methods of using gm604 in modulating als disease biomarkers leading to prognosis and therapeutic treatment for als disease
CN110381981A (zh) * 2016-12-23 2019-10-25 健能万生物制药公司 在诊断和治疗阿尔茨海默病中使用gm6的方法
WO2018129421A1 (en) * 2017-01-09 2018-07-12 Genervon Biopharmaceuticals, LLC A promising drug candidate for parkinson's disease
MX2020012532A (es) * 2018-05-31 2021-04-28 Immunity Pharma Ltd Composiciones y procedimientos de su uso para el tratamiento de esclerosis lateral amiotrofica (ela).

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6841531B2 (en) * 1996-09-27 2005-01-11 Genervon Biopharmaceuticals Llc Methods and use of motoneuronotrophic factors
US6309877B1 (en) * 1996-09-27 2001-10-30 Km Biotech, Inc. Polynucleotides encoding motoneuronotrophic factors
DK1587526T3 (da) * 2003-01-21 2012-02-06 Genervon Biopharmaceuticals Llc MNTF-peptider og sammensætninger og anvendelsesmåder

Also Published As

Publication number Publication date
WO2008057609A4 (en) 2009-01-29
WO2008057609A3 (en) 2008-12-18
HK1137623A1 (en) 2010-08-06
US20090048162A1 (en) 2009-02-19
US8673852B2 (en) 2014-03-18
AU2007317730B2 (en) 2014-01-09
CN101534648A (zh) 2009-09-16
EP2086331A4 (en) 2010-08-25
EP2086331B1 (en) 2013-03-27
WO2008057609A8 (en) 2008-08-28
AU2007317730A1 (en) 2008-05-15
EP2086331A2 (en) 2009-08-12
JP2010509345A (ja) 2010-03-25
CA2669658C (en) 2017-12-12
WO2008057609A2 (en) 2008-05-15
CA2669658A1 (en) 2008-05-15
JP5336384B2 (ja) 2013-11-06
DK2086331T3 (da) 2013-05-27
ES2407454T3 (es) 2013-06-12

Similar Documents

Publication Publication Date Title
CN101534648B (zh) 使用mntf肽及其类似物治疗神经紊乱的方法
US10330671B2 (en) Modulation of synaptic maintenance
JP2013177388A (ja) 幹細胞のｍｎｔｆ分化および成長
AU2011314074B2 (en) ND2 peptides and methods of treating neurological disease
JP5718649B2 (ja) Ｍｎｔｆペプチド組成物およびその使用法
CN113260373B (zh) 用于诱导神经可塑性的方法和组合物
HK1137623B (en) Methods of treating neuronal disorders using mntf peptides and analogs thereof
HK1125824B (en) Mntf differentiation and growth of stem cells
HK1151242B (en) Mntf peptide compositions and methods of use

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1137623

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1137623

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20131211